{
  "docId": "019de077-0ff3-70e8-97e9-f8df18ead978",
  "docSlug": "2f90f1dc6d9440d196c6f2643a698403",
  "documentTitle": "OmniAb | Results Presentation Deck | 24 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 24,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a list-based layout with icons to highlight three strategic pillars.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0ff3-70e8-97e9-f8df18ead978/14",
  "deckHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978",
  "deckJsonHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978.json",
  "deckAnchorHref": "/decks/019de077-0ff3-70e8-97e9-f8df18ead978#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.66
      },
      "kind": "list",
      "text": "Continue to focus on innovation, expansion of the technology platform and introduction of new technology and partner experience enhancements",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47924470-dbc1-4dec-999c-1c825879ceda",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.26
      },
      "kind": "list",
      "text": "Late-stage advancement and data events expected for key clinical programs at Genmab, Immunovant and others(1)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afaf17a7-8f98-49e5-9120-5e432532ee91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.1,
        "y": 0.46
      },
      "kind": "list",
      "text": "Leverage fully-staffed business development team for deal expansion globally",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccb3c39f-fbb9-457f-8509-dc1b593657d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.04,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "(1) Genmab/BioNTech: Acasunlimab - Genmab plans to initiate a Phase 3 study of acasunlimab in a second-line non-small cell lung cancer indication in 2024. Immunovant/Hanall Biopharma: Batoclimab - Immunovant expects Phase 2b data in chronic inflammatory demyelinating polyneuropathy in 2Q or 3Q 2024 and Phase 3 topline data in Myasthenia gravis in 2H24, IMVT-1402 - Immunovant announced plans to initiate new potentially registrational programs for IMVT-1402.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaba244e-a6bd-4c59-a15b-dd78b6b1af95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "2024: Looking Ahead To Continued Progress",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e893c710-9f4e-4520-a760-254d3cc78f91",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "title",
      "text": "PIPELINE GROWTH AND ADVANCEMENT, NEW DEALS AND TECHNOLOGY DEPLOYMENT",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e423b5b-069e-4bca-8a75-30c3834fe92c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "b9ee6a37-37d0-46d3-a6e0-e21b7513d05b",
      "evidence": "Continue to focus on innovation, expansion of the technology platform and introduction of new technology and partner experience enhancements",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 14,
      "beatId": "c4383dba-22a9-4589-8e9b-ca01b7b4f140",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with a call to action and Q&A",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "3d5a1a82-3964-408b-9b7e-ec01e0958d5f",
      "evidence": "The presentation outlines the company's strategy and progress",
      "position": 1,
      "objective": "Presenting a clear plan for growth",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}